US2015087713A1PendingUtilityA1

Enhanced bimatoprost ophthalmic solution

77
Assignee: ALLERGAN INCPriority: Mar 16, 2005Filed: Dec 5, 2014Published: Mar 26, 2015
Est. expiryMar 16, 2025(expired)· nominal 20-yr term from priority
Inventors:Chin-Ming ChangJames N. ChangRhett M. SchiffmanR. Scott JordanJoan-En Chang-Lin
A01N 33/12A61K 31/165A61K 47/12A61K 31/5575A61K 31/557A61K 31/14A61P 27/14A61K 9/0048A61P 27/02A61P 27/06A61K 47/02A61K 47/18A61K 9/08
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An ophthalmic composition comprising about 0.01% - 0.015% w/v bimatoprost and about 0.02% w/v benzalkonium chloride. 
     
     
         2 . The ophthalmic composition of  claim 1 , wherein the composition comprises about 0.01% w/v bimatoprost. 
     
     
         3 . The ophthalmic composition of  claim 1 , wherein the composition comprises 0.01% w/v bimatoprost. 
     
     
         4 . The ophthalmic composition of  claim 1 , wherein the composition comprises about 0.015% w/v bimatoprost. 
     
     
         5 . The ophthalmic composition of  claim 1 , wherein the composition comprises 0.015% w/v bimatoprost. 
     
     
         6 . The ophthalmic composition of  claim 1 , wherein the composition comprises 0.02% w/v benzalkonium chloride. 
     
     
         7 . The ophthalmic composition of  claim 1 , wherein the composition further comprises dibasic sodium phosphate. 
     
     
         8 . The composition of  claim 1 , wherein the first composition further comprises citric acid monohydrate. 
     
     
         9 . The composition of  claim 1 , wherein the composition further comprises sodium chloride. 
     
     
         10 . The composition of  claim 1 , wherein the first composition further comprises hydrochloric acid and sodium hydroxide to adjust the pH. 
     
     
         11 . The composition of  claim 1 , wherein the composition further comprises water. 
     
     
         12 . The composition of  claim 1 , wherein the first composition has a pH of about 7.3. 
     
     
         13 . The composition of  claim 1 , wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 
     
     
         14 . The composition of  claim 13 , wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily. 
     
     
         15 . The composition of  claim 13 , wherein the composition is applied to the eyes of a human patient suffering from elevated intraocular pressure at least once a day. 
     
     
         16 . The composition of  claim 13 , wherein the composition applied once daily lowers intraocular pressure more effectively than the second composition applied once daily. 
     
     
         17 . The composition method of  claim 13 , wherein the composition applied once daily is effective for treating glaucoma. 
     
     
         18 . The composition of  claim 1 , wherein the composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride, and when applied once daily to the eyes of a human patient suffering from elevated intraocular pressure, lowers intraocular pressure and results in less hyperemia than a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride. 
     
     
         19 . The composition of  claim 18 , wherein the composition applied once daily lowers intraocular pressure as effectively as the second composition applied once daily. 
     
     
         20 . The composition method of  claim 18 , wherein the composition applied once daily is effective for treating glaucoma.

Join the waitlist — get patent alerts

Track US2015087713A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.